Send to

Choose Destination
Br J Haematol. 2011 Mar;152(5):512-23. doi: 10.1111/j.1365-2141.2010.08486.x. Epub 2011 Jan 20.

Optimal management of β thalassaemia intermedia.

Author information

Department of Internal Medicine, Division of Haematology & Oncology, American University of Beirut Medical Centre, Riad El Solh 1107 2020, Beirut, Lebanon.


Our understanding of the molecular and pathophysiological mechanisms underlying the disease process in patients with β thalassaemia intermedia (TI) has substantially increased over the past decade. The hallmark of disease process in patients with TI includes ineffective erythropoiesis, chronic haemolytic anaemia, and iron overload. There are a number of options currently available for managing patients with TI including splenectomy, transfusion therapy, iron chelation therapy, modulation of fetal haemoglobin production, and several other agents targeting specific clinical complications. Limited studies assessed the efficacy and safety of these modalities; hence, there are currently no clear guidelines for managing patients with TI. Until solid evidence-based guidelines are available, individualised treatment should be entertained.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center